Impel NeuroPharma announces agreement with Camargo Pharmaceutical Services

According to intranasal drug developer Impel NeuroPharma, the company has signed service agreements with 505(b)(2) development specialist Camargo Pharmaceutical Services. Camargo will provide development services for products based on Impel’s Precision Olfactory Delivery (PODTM) intranasal delivery platform.

In December 2016, Impel announced that it had raised up to $36 million for development of intranasal CNS products, including therapies for migraines and for Alzheimer’s disease.

Impel NeuroPharma CEO and Co-Founder John Hoekman said, “Camargo has a deep experience in 505(b)(2) strategy and combination product development which perfectly complements Impel’s capabilities. Partnering with Camargo will allow Impel to take full advantage of our POD nasal drug delivery platform and efficiently develop multiple meaningful drug products.”

Camargo CEO Ken Phelps added, “By bringing together Camargo’s expertise with 505(b)(2) drug development and Impel Neuropharma’s revolutionary POD technology, we are able to help enable effective new therapies for patients worldwide. By utilizing the 505(b)(2) pathway and employing best strategies, Impel’s products will move through approval and reach the market in the most cost- and time-effective manner.”

Read the Impel NeuroPharma press release.